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In an attempt to simulate conditions in the human population between epi- 
demics of influenza, the influenza A virus (PR8 strain) has been serially passed 
in mice  partially immunized with  this  virus.  The  antigenic variant which 
emerged in the course of these passages has been described  (1). This variant 
was capable of multiplying in the lungs of vaccinated mice which were fully 
resistant to challenge with the parent PR8 strain. It was shown by cross-sero- 
logical tests that the variant contained a new dominant antigen, but that it 
also retained antigens related to the parent PR8 strain. Because there was no 
further alteration in the antigenic composition  of the variant after the 17th 
passage  in PRS-immunized mice,  passages  were  carried in mice  immunized 
to the variant. The present report describes the production and characteriza- 
tion of a series of three variants, each derived in succession from the previous 
one,  and compares  them with the parent  PR8  strain and the first variant 
strain (1). 
Materials and Methods 
Several of the methods employed are similar to those previously described in detail  (1). 
These will be briefly reviewed in the present report. The additional techniques used include 
the complement-fixation test and antibody absorption. 
The PR8  influenza A  strain  was  initially employed as  the parent  virus  (1).  The stock 
suspensions of PR8-infected mouse lung were prepared from mice infected by the air-borne 
route in a  closed chamber and  sacrificed  48  hours  later  (2).  10 per cent suspensions  were 
frozen in aliquots and stored at --40°C. Broth used for lung suspensions and for all dilutions 
contained 1,000 units/ml, of penicillin and 1 mg./ml, of dihydrostreptomyein. Viral antigens 
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for  hemagglutination  (H.A.)  tests,  hemagglutinin-inhibition  (H.I.)  tests,  neutralization 
tests, antibody absorption tests, and vaccine were prepared in eggs by inoculation of diluted 
mouse lung suspension intraallantoically. Only first egg passage material was used (I). Virus 
titrations in eggs were carried  out  by inoculating 0.1  ml.  of falling 10-fold  dilutions into 
four 10 to 11 day old chick embryos for each dilution and testing individual allantoic fluids 
for  chicken red  cell hemagglutinafion after 48  hours'  incubation at  37°C.  and  overnight 
chilling (3). The EIDr0 was calculated by the method of Reed and Muench (4). 
Inoculation of mice for serial passage was by the intranasal route using light ether anes- 
thesia. Mice used for serial passage were vaccinated with one to three intraperitoneal doses 
of formol-inactivated virus at weekly intervals. From  10  to  14 days after the last dose of 
vaccine the mice were bled from the tail vein and the sera tested individually for H.I. anti- 
body titers by the modified Salk pattern test (5). In the initial passages of the variants in 
homologously immunized animals it was necessary to employ mice of low antibody titers. 
As the number of passages increased, mice with gradually increasing antibody titers were 
selected  until virus growth  could  be maintained in  the presence of high antibody levels. 
With each passage the immunized mice were inoculated intranasally under light ether anes- 
thesia with a  0.05 ml. of a  10 per cent mouse lung suspension of the respective strains. 48 
hours after inoculation the animals were sacrificed. Ten per cent mouse lung virus suspension 
was  then prepared  and titrated in eggs before passage  into the next  group  of vaccinated 
mice. 
Antisera for all strains of virus were prepared by infecting ferrets in the cloud chamber 
and bleeding them 14 to 21 days after infection (1). All sera for H.I. tests were first treated 
with RDE to remove non-specific inhibitors of hemagglutinin inhibition (6). 
Complement-Fixation  Tests.--The complement-fixation test described  by Lennette st  al. 
was employed (7). The viral antigens (600 S fraction) were prepared according to the method 
of Wiener, Henle, and Henle (8). Fixation was carried out overnight at 4°C.  and the titers 
are expressed as the initial serum dilution showing 50 per cent fixation. 
Ant4.body Absorption  Tests.--A  modification of  the  technique described  by Walker  and 
Horsfall  (9)  was used.  Freshly harvested allantoic fluid virus was concentrated by adsorp- 
tion and elution. Three times washed chicken red blood cells were added to chilled allantoic 
fluid virus in 2 per cent final concentration and the mixture was held at 2°C. for 90 minutes. 
Following removal of the supernate the virus was eluted at 37°C.  into buffered saline, ~o 
of the original volume, for a  period of 2  to 3  hours.  The eluate had an H.A.  titer of 8,000 
to 16,000  per ml. 2 ml. aliquots of the eluate were centrifuged at 39,000 g for 40 minutes 
(Spinco model L  preparative centrifuge, rotor No. 40), the supernate was discarded and the 
virus pellet was resuspended in 2 ml. of ferret antiserum which had been diluted with equal 
volumes of RDE and nutrient broth to 64 H.I. units per 0.2 ml. The serum virus mixtures 
were held overnight at 4°C. followed by removal of the virus by centrifugation at 39,000 g 
for 40  minutes.  Three  successive  cycles  of absorption were  carried out with  each  serum. 
Traces  of residual viral hemagglutinins and excess RDE  were inactivated by heating the 
supernate  at  65°C.  for  30  minutes.  Antibody  absorption was  considered  satisfactory  (a) 
when all homologous antibody was removed in one absorption cycle, and (b) when the heter- 
ologous  titer  showed  no  further  changes  after  two  successive  absorptions.  All  sera 
were titrated by the hemagglutinin-inhibition test and the titers are expressed as the recip- 
rocal of the initial serum dilution causing complete inhibition of hemagglutination of four 
agglutinating doses of virus. 
RESULTS 
Nomenclature  of  Variant  Strains.--Upon  initiation of  experiments  to  develop  variants 
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in order to keep the relationship of one to the other clear. This is shown in Table I. The 
PR8 parent strain is referred  to as stock (S), and the first variant, referred  to as PR8-T in 
the previous report (1), is renamed As, or variant A produced by serial passage in PR8-S-- 
vaccinated mice. The second variant, derived from  the first, is called Ba, the third Cb, and 
the fourth Dc. In each case the small letter indicates the strain used to vaccinate the mice. 
The numbers following these letters give the number of the serial passage in vaccinated mice 
at which maximum  antigenic change  occurred  (Table I). 
The appearance of the influenza virus variants in the course of serial pas- 
sages in vaccinated mice was a  gradual one. In early passages, the virus multi- 
plied only in the lungs of mice with relatively low H.I.  titers (1:40  to 1:80). 
Selection of mice with the same or with higher H.I. titers for the next passage 
was made on the basis of the egg infectivity titer of the lung suspension from 
the last passage. Variation in antibody levels among mice receiving the same 
vaccine made necessary the prior determination of individual titers (1). 
TABLE I 
Summary of Derivation of Antigenic Variants of Influenza PR8-S Virus 
Virus inoculated 
intranasally 
PR8-S 
As 
Ba 
Cb 
Virus used for 
immunization of mice 
for passage 
PR8-S 
As 
Ba 
Cb 
No. of passages* 
14 
22 
15 
14 
Variant isolated 
As~ 
Ba 
Cb 
De 
* Indicates passage number at which maximal antigenic deviation occurred. 
~: Referred to in previous paper (1) as PR8-T. 
Antigenic  Stability  and Homogeneity  of Variant Strains  of PRS-S  Viru~.-- 
When further alteration in antigenic composition of the new strain as compared 
with its parent failed to occur during serial passage, it was passed in normal 
mice by the  intranasal route for  18  to  24  passages. The final normal mouse 
passage was,  in  each  case,  found  to  be  identical antigenically with  the  last 
passage in vaccinated mice. In addition, one variant,  Cb,  was passed in eggs 
at  10  -~ dilution serially for twelve passages without  any change  in antigenic 
composition. 
To determine the extent of antigenic homogeneity of the variants and the parent PR8-S 
strain, each strain was tested by the limiting dilution technique.  Groups of twelve eggs were 
inoculated intraallantoically with 0.5 log increment dilutions near the EID60 of a particular 
mouse-lung virus suspension.  The positive fluids from individual eggs in the group in which 
25 per cent or less of the total were infected were again passed at limiting dilutions in eggs. 
No  serological  differences  were  detectable  among  the  individual  fluids 
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Serological  Characteristics  of  the  Variants.--The  results of  cross-H.I,  tests 
(Table II),  cross-complement-fixation tests  (Table  III),  and  cross-neutrali- 
TABLE II 
Cross-Hemagglutinin-Inhibition  Tests  with  Parent  (PR8-S)  Influenza  Virus  and  Variant 
Strains 
Test viruses 
PR8-S 
As22 
Ba25 
Cbl7 
Dc26 
Lee 
Convalescent  ferret antlsera 
PRS-S 
2580* 
320 
40 
16 
32 
<10 
As22 
640 
1280 
80 
16 
40 
<10 
Ba25 
160 
160 
320 
32 
80 
<10 
Cbl7 
320 
160 
320 
640 
160 
<I0 
Dc26 
320 
320 
320 
320 
320 
<10 
* Reciprocal of initial dilution. 
TABLE III 
Cross-Complement Fixation  Tests with Parent (PR8-S)  Virus and Antigenic  Variants 
Convalescent  ferret antisers 
Test viruses 
PRS-S  As22  Ba2S  C  bl  7  Dc26 
PR8-S 
As22 
Ba25 
Cbl7 
Dc26 
Lee 
512 
64 
16 
10 
16 
<8 
128 
128 
32 
16 
32 
<8 
128 
128 
128 
16 
32 
<8 
128 
128 
128 
258 
64 
<8 
128 
128 
128 
128 
256 
<8 
TABLE IV 
Cross-Neutralization Tests in Eggs with PR8-S Virus and Antigenic  Variants 
Convalescent  ferret antisera 
Test viruses 
PR8-S  As  22  Ba25  Cbl7  Dc26 
PR8-S 
As22 
Ba25 
Cb17 
Dc26 
2580 
80 
28 
7 
17 
453 
1019 
50 
14 
57 
57 
113 
226 
12 
113 
57 
64 
80 
510 
40 
113 
120 
120 
80 
226 
zafion tests (Table IV), show the progressively decreasing titers of each suc- 
cessive variant with PR8-S  antiserum. This appeared  to  reach  the point of 
greatest deviation with Cb. Variant Dc had slightly, but consistently, higher 
titers with PR8-S antiserum in all three tests. A  similar pattern of serological PAUL GERBER,  DOROTHY HAMP.E~ CLAYTON  O. LOOSLI  417 
relationship is noted when the variants are compared to one another. Antisera 
of all of the variants crossed with PlZS-S virus to almost the same titer as the 
homologous virus in the H.I. and complement fixation tests, while in the neu- 
tralization test there was less crossing with PR8-S.  This is in agreement with 
previous reports that cross-neutralization  tests tend to show greater immuno- 
logical differences than cross-HH.I, tests (10, 11). 
A more precise definition of antigenic structure of the variants was obtained 
by antibody absorption  tests.  The  results,  presented  in  Fig.  1,  show  that 
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FIG.  1.  H.I.  titers of ferret antisera before and after absorption  with homologous virus 
or PR8-S  virus.  (Black columns are titers after absorption.) 
absorption of PR8-S antiserum with PR8-S virus removed all PR8-S antibody 
and,  therefore,  eliminated the  titer of this serum with each of the variant 
viruses.  Absorption of As, Ba, Cb, and Dc antisera with PlZ8-S removed the 
PR8-S  antibody and reduced the titers to the homologous viruses by varying 
degrees. It is apparent that Cb antiserum contained less PlZ8-S antibody than 
did the antisera of the other variants. However, when the PRS-S antisera and 
the antisera to each variant were absorbed with homologous virus, as shown 
in the lower half of Fig.  1, all variants reduced the titer of PR8-S  antiserum 
to about the same extent when tested with PR8-S virus, although the titer to 
each variant was eliminated. The same absorbing  dose of each variant com- 
pletely removed the antibody in its own antiserum, and the crossing antibody 
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These results  indicated  that  the variants shared antigens with PR8-S but 
in addition contained specific components. In Table V which gives the relative 
amount of antigen  shared  by each variant  with  PRS-S,  it  is again  obvious 
that Cb contains less PR8-S antigen than strain Dc which was derived from Cb. 
Immunogenic,  Properties  of the  Variant  Viruses.--The  observation that  the 
variant strains continued to produce considerable amounts of antibody react- 
ing with PR8-S in spite of their decreasing reactivity with PR8-S antiserum 
might  have  been  a  reflection  of  differences  in  antigenicity between  PR8:S 
and the new specific components. Results of the serological tests indicated that 
the  variants  became  progressively poorer  antigens,  as  shown  by  the  lower 
homologous titers.  Furthermore,  this was also noted during the development 
of  the  strains,  when  intraperitoneal  vaccination  of  mice  with  the  variants 
produced lower antibody titers.  If the antigenicity of PR8-S is greater  than 
TABLE V 
Homologous 1t.1. Titers of Ferret Antisera before and after Absorption with PR8-S Virus 
Sera 
PR8-S 
As22 
Ba25 
Cb17 
Dc26 
Unabsorbed 
64* 
64 
64 
64 
64 
Absorbed with 
PRS-S 
<2 
4 
6 
16 
6 
PR8-S antibody 
absorbed 
p~csnt 
1~.0 
~.7 
~.6 
75.0 
90.6 
Specific antibody 
remaining 
0.0 
6.3 
9.4 
25.0 
9.4 
* All sera were diluted to 64 H.I. units before absorption. 
that of the dominant antigen of each variant, then the reduction in the amount 
of PR8-S component in the antigenic composition of the variants would not 
be reflected by a  comparable decrease in  the  titer  of PR8-S antibodies pro- 
duced. 
To test this hypothesis, antigenicity tests with each variant and with PR8-S virus were 
carried out. Mice weighing 20 to 24 gm. were injected with twofold dilutions in buffered 
saline of allantoic fluid virus having 1024 H.A. units/ml. Six mice were used per dilution, 
each receiving 0.5 ml. intraperitoneally. 2 weeks later the animals were exsanguinated from 
the axillary vessels and the blood from each group pooled. The homologous H.I. antibody 
titers were then determined and the results are presented in Fig. 2. A marked decrease in 
the ability of variant strains to provoke antibodies as compared with the parent PR8-S 
virus is evident. Even in high concentrations the variants failed to stimulate antibodies to 
as high a titer as PR8-S. Furthermore, PRS-S diluted 1:2560 still elicited antibodies while 
Cb diluted 1:320 failed to do so. 
These results indicated that differences in the immunogenic properties are 
indeed  involved  in  the  serological  relationship  between  the  parent  virus, 
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Mouse Protection  Tests.--For further  evidence of the  degree of deviation 
from PRS-S, protection tests in mice vaccinated with PRS-S and  challenged 
with As22,  Cbl7, and PR8-S, and in mice passively immunized with PR8-S 
rabbit antiserum and challenged  with Cbl7 and PR8-S were carried out. 
Active Immunization.-- 
•  .\  o  To compare the protection afforded by tmmumzatmn with PR8-S vaccine against intra- 
nasal challenge with PR8-S, As22, and Cbl7, mice were vaccinated intraperitoneally with a 
single dose of 0.5  ml. of formol-inactivated  PR8-S vaccine. The H.I. antibody titers,  de- 
termined  10 days later by bleeding about half of the mice from the tail vein, ranged from 
1:320 to  1:640. Because of the large number of animals involved in the experiment, they 
were divided into two groups and successively challenged. Groups of ten vaccinated mice 
6¢0 
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160  --  &  .t,,  Bo -25 
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5  I0  20  40  80  160  320  64.0  1280  2560 
VACCINE  DILUTION 
FIG. 2. A comparison of the antigenicity of PR8-S virus with that of the variant strains. 
The homologous H.I. titers for each virus strain are shown. 
and an equal number of controls were challenged intranasally with 105, 104, and 108 LDs0 of 
the respective virus. 72 hours later three mice in each group Were killed for lung virus titer 
determinations.  The remaining mice were observed for death  or survival for 10 days. The 
results are given in Table VL 
All unvaccinated control mice developed high  virus titers in their lungs at 
3 days and the remaining mice all died by the 6th day with extensive pulmo- 
nary consolidation.  Solid homologous protection was indicated by the lack of 
virus  growth  and  survival  of all  vaccinated mice  challenged  with  all  three 
doses of PR8-S virus. 
The effect of challenge with the variants depended on the amount of virus in 
the infecting dose. With the highest challenge  dose of As and Cb, some of the 
animals  died with extensive pulmonary consolidation,  but the significance  of 
the difference in  the number of deaths was uncertain in view of the small size 420  ANTIGENIC  VARIANTS  01~  INFLUENZA  A  VIRUS. II 
of the sample. No deaths occurred with the two smaller challenge doses. Both 
variants multiplied in the lungs of immunized mice  to similar  titers.  Thus, 
PRS-S  vaccine  failed to  protect  mice  against infection  with both variants 
regardless of challenge dose, and, in some cases, failed to prevent death result- 
ing from infection with the highest dose.  However,  the fact that Cb reacted 
with PR8-S antiserum in vitro to much less extent than As was not reflected in 
vivo by a higher mortality in PR8-S vaccinated mice challenged with Cb. 
Passive Immunization.--Further evidence for cross-protection of Cb-infected 
mice was obtained by passive immunization with PR8-S antiserum. 
Antiserum was prepared by injecting rabbits intravenously with 5  ml.  of concentrated 
PR8-S virus daily for 2 successive days. The animals were bled 15 days after the last injec- 
TABLE  VI 
Results of Challenge Test of Mice Immunized with PR8-S Vaccine 
Challenge  Vaccinated mice  Unvaccinated  mice 
Virus  LDio dose 
PR8-S 
cc 
As22 
cc 
¢c 
Cbl7 
t~ 
tt 
lO  s 
104 
lO  s 
10  ~ 
104 
lO  s 
105 
104 
lO  s 
72 hr. lung virus  Deaths at 
titer EIDso  10 days 
<1  0/7* 
< 1  0/7 
<l  0/7 
6.0  2/7 
6.3  0/7 
5.0  0/7 
6.3  3/7 
6.0  0/7 
s.0  0/7 
72 hr. lung virus 
titer EID. 
9.0 
9.0 
9.0 
8.7 
9.2 
9.0 
9.0 
8.7 
8.7 
Deaths at 
10  days 
7/7 
7/7 
7/7 
7.7 
7/7 
7/7 
7/7 
7/7 
7/7 
* Numerator =  No. of mice which died; denominator -- No. of mice inoculated. 
tion and the titers of the pooled sera were 640  (H.I.) and 600  (neutralizing) against PR8-S 
antigen, and 160 (H.L) and 40 (neutralizing) against Cb antigen. A large group of mice was 
given two doses, each 0.5  ml., of rabbit antiserum intraperitoneally, one 12  hours and one 
immediately before infection. These doses were followed by intraperitoneal doses of 0.25 ml. 
8, 24, and 48 hours after infection. The passively immunized mice and control mice (given 
normal rabbit serum in the same way) were each divided into two groups one of which was 
infected by aerosol (12) with  100 LADs0 of PR8-S virus and the other with 100 LADs0 of 
Cb  variant,  t  Following challenge in the cloud chamber,  ten mice in  each group were set 
aside for observation of death or survival. At intervals three mice from each group were bled 
for H.I. antibody titer after which the lungs were removed and the virus content titrated in 
eggs. The lungs of one mouse killed at each interval were fixed and prepared for microscopic 
study of the pathology. The results of this experiment are shown in Table VII. 
The cross-protection  noted in actively immunized mice is evident also  in 
this experiment with passively immunized mice. While none of the passively 
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immunized mice died,  those infected with Cb showed considerable growth of 
virus in the lung.  On the other hand,  virus was present in the lungs of mice 
infected with PR8-S only at 48 hours after infection,  and then the titer was 
very low. 
TABLE VII 
Results  of Challenge of PR8-S Passively  Immunized Mice with PR8-S and Cb Variant Strains 
Control Mice  Passively  immunized mice 
Time after infection  H.I. titer versus 
Dead*  Lung~t  H.I. 
titer  tater 
Dead  I  Lung 
Tot~  titer  PR8-S  Cb 
Challenged ~Ath 100 LADso PR8-S 
6 hrs. 
24  " 
48  " 
4 days 
6  " 
10  " 
14  " 
21  " 
o/lo 
O/lO 
o/lo 
5/10 
10/10 
4.2 
8.7 
9.7 
9.0 
<10 
<10 
<10 
<10 
<10 
o/10 
O/lO 
o/lo 
o/lo 
O/lO 
O/lO 
0/10 
o/lo 
o/io 
I 
Challenged with 100 LADno Cb 
<1.0 
<1.0 
2.0 
<1.0 
<1.0  80 
240 
60 
15 
<10 
160  120 
160  120 
240  80 
160  80 
60 
60 
30 
20 
<10 
6 hrs. 
24  " 
48  " 
4 days 
6  " 
8  " 
10  " 
14  " 
21  " 
O/lO 
O/lO 
o11o 
o/lo 
8/lO 
10/10 
3.5 
8.5 
8.5 
8.7 
<10 
<10 
<10 
<10 
<10 
o/Io 
o/lo 
O/lO 
o/lo 
O/lO 
O/lO 
o/lo 
O/lO 
0/10 
<1.0 
3.8 
5.5 
4.7 
5.0 
4.7 
<i.0 
160 
160 
240 
120 
120 
6O 
<10 
120 
160 
120 
120 
80 
40 
40 
<10 
<10 
*  Cumulative. 
EID~o. 
The gradual disappearance of antibody, without the expected boost in fiter 
which usually follows infection and recovery, has been described in previous 
experiments (12) and is believed to result from blockage of virus from reaching 
the sites of antibody formation by the passively circulating antibody. 
DISCUSSION 
The  results reported  in  this  study indicate  that  successive  generations  of 
variants of PR8-S virus exhibit a progressive deviation from the parent virus 
characterized by decreasing reactivity with PR8-S antiserum. Cross absorption 422  ANTIGENIC  VARIANTS  OF  INFLUENZA  A  VIRUS.  II 
tests demonstrate that the variants share antigens with the parent PR8-S virus 
but  differ from  it  by  the  presence  of  specific  antigenic components  which 
increase in quantity in each successive variant, while the amounts of related 
antigens show a  progressive decrease.  Strain Dc26,  however, contains more 
PR8-S  component than  its  parent  strain  Cb.  This would suggest  that  the 
development of further variants from variants may demonstrate a closer rela- 
tionship eventually with PR8-S. These studies are now in progress. 
Although the pathogenicity of the variants remains essentiaUy the same as 
that of the parent virus their ability to stimulate antibodies shows a progres- 
sive decrease. This interesting phenomenon is under further study. 
The fact that the variants retain the ability to elicit antibody to PR8-S in 
spite of the progressive decrease of the PR8-S  component in their antigenic 
mosaic is in some respects reminiscent of the P-Q variation described by Van 
der Veen and Mulder (13).  However, the properties of the antigenic variants 
in this study differ from the P-Q changes for the following reasons:-- 
(a) Fiset and Depoux (14), on the basis of absorption tests, inferred that Q strains 
contain their major antigens  inside the virus particle in a location where it is not 
readily available for antigen-antibody reactions in vitro, but may, nevertheless, cause 
the formation of antibody when injected into an animal. The results obtained in this 
study do not indicate the presence of PRS-S antigen in a subsurface position in the 
virus particle  of the variant strains  because absorption  of variant antiserum by its 
homologous virus eliminated the titer to both homologous virus and to PR8-S. Had 
PRS-S  antigen been  masked,  the  titer  to PR8-S  virus  would have remained  un- 
changed. 
(b) According to Isaaes et a/. (15), P-Q phase variation is a reversible phenomenon. 
Passage of P  virus in fertile  eggs in the presence  of subneutralizing  doses  of ho- 
mologous antiserum results in a change to the Q phase and, conversely, virus reverts 
to the P phase following few passages in normal mice. In contrast to these findings, 
the variants described in this study were shown to retain their antigenic  character 
after repeated passages in normal mice, and in eggs (Cb variant). 
(c)  Most Q viruses described by Isaacs  are characterized  by the production  of 
higher heterologous than homologous antibodies. This was never observed with any 
induced variants in this investigation. 
The results of the antigenicity tests support the hypothesis that some of the 
PR8 component of the variants is being replaced by different but poorer anti- 
gens. Thus, the amount of PR8 antibody produced by the variants continues 
to be relatively considerable. 
The fact that PRS-S vaccine protects mice against fatal infections with large 
doses (104 LD60) of the highly pathogenic variant viruses, although the latter 
show a  progressive decrease in serological reactivity with PRS-S  antiserum, 
points up  the  necessity for evaluating the  significance of antigenic changes 
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that  the  variants  continue  to  share  antigenic  components  with  the  PR8-S 
strain in sufficient quantities to prevent unrestricted virus growth of the vari- 
ants  in  the  lungs  of PR8-S  vaccinated  mice  and  the  fatal  outcome of the 
infection. 
Since the publication of the first paper (1) of this series, Magill (16) reported 
the results of his study of influenza  A prime virus propagated in immunized 
mice resulting in the emergence  of antigenic variants. However, the differences 
in techniques employed in the characterization  of the variants make a direct 
comparison of his findings with ours difficult. 
The problems encountered in the prophylaxis of influenza  by vaccination as 
a result of strain deviation in the Type A group are well established (17, 18). 
Recent evidence  (19)  of major  antigenic  changes occurring  in  the  B  group 
points up  the  importance of this phenomenon.  Although  there are probably 
many factors influencing  the  development of  antigenic variants  of influenza 
viruses during  natural  transmission  in the human  population,  the  results  of 
this and other studies  (10, 16) emphasize  the role of the immune  state of the 
host.  In view of the  limited number  of passages carried  out in mice in our 
laboratory, as compared to the large number which occur during a single  epi- 
demic in man,  it  seems possible that  the  changes shown by these  variants 
represent only a step in the antigenic alteration that can occur in influenza  A 
virus.  Therefore,  passages of  Dc variant  in homologously immunized  mice, 
and the succeeding steps in this progression of passage are now in progress. 
SUMMARY 
Four successive  generations of antigenic variants of influenza  PR8-S virus, 
each derived from the previous one by serial  passage in the lungs of mice im- 
munized with the homologous agent, were compared with the original  parent 
PR8-S virus with respect to their serological  and immunological  character. It 
was  demonstrated  by means  of H.I.,  complement-fixation  and  in  ovo-neu- 
tralization  tests  that  the  variants  exhibited a  progressively  decreasing  re- 
activity with the parent PRS-S antiserum while retaining  the ability to elicit 
antibody to PR8-S influenza  virus and to  their  respective predecessors. Ac- 
companying these changes was a progressive reduction in antigenicity without 
any significant  changes in pathogenicity for mice. Experimental evidence was 
presented  which  indicates  that  the  serological  changes observed  with  the 
variants are not related to the P-Q phenomenon. 
Antibody  absorption  tests  showed  that  the  variants  share antigens  with 
PR8-S virus but differ  from it by the presence of specific  antigenic  compo- 
nents; these increase in quantity with each successive variant while the amount 
of related antigens shows a progressive decrease. 
The importance of evaluating the significance  of antigenic changes of influ- 
enza  viruses with  active  immunity  tests  was  emphasized  by  the  fact  that 424  ANTIGENIC  VARIANTS  OF INFLUENZA  A  VIRUS. II 
PR8-S vaccine protected mice against  fatal infection with lethal doses of the 
variant  strains  although  the latter  had  a  progressively decreasing  serological 
reactivity with PR8-S antiserum. 
The  inheritable  character  of  the  new  antigenic  properties  of  the  variant 
strains  was demonstrated  by their  persistence  in the absence of the selective 
environment following 18 to 24 serial intranasal  passages with large inocula in 
normal mice and following limiting dilution passage in fertile eggs. 
The technical assistance of Richard C. Ewert is gratefully acknowledged. 
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